Morningstar

Bio-Techne Corp TECH

Morningstar Rating
Unlock
Stock XNAS Rating as of
$72.40 −0.07 (0.10%)
View Full Chart
As of Delayed Price Pre-Open: $72.42 +0.01

Company Report

View Archive

Bio-Techne To Be Acquired by Merck KGaA

Jay Lee

Bio-Techne is a market leader in proteins, immunoassays, clinical diagnostic controls, and other reagents that are crucial for the academic, biopharmaceutical, and diagnostic markets. On June 25, 2026, Merck KGaA announced a proposed acquisition of Bio-Techne, which is expected to close by late 2026 or early 2027.

Read Analysis

Price vs Fair Value

View History
TECH is trading at a LOCK|#xrL@p premium.
Price
$72.40
Fair Value
pJS
Uncertainty
LOCK|w&
1-Star Price
LOCK|<.h@
5-Star Price
LOCK|.!
Economic Moat
LOCK|?$$%b
Capital Allocation
LOCK|$%^tx&@

Bulls Say, Bears Say

Bulls

The firm's reputation for excellent proteomic reagents and instruments allows it to generate high profit margins and strong cash flow.

Bears

Bio-Techne's long-term strategy relies on acquisitions, and the company may have difficulty finding suitable targets because of high valuations or scarcity. Additionally, it may fail to successfully integrate and scale up an acquired business.

Show More

News

View All

Trading Information

Previous Close Price
$72.47
Day Range
$72.38–72.54
52-Week Range
$43.20–72.69
Bid/Ask
$72.36 / $72.75
Shares Outstanding
156.82M
Market Cap
$11.35B
Volume/Avg
126 / 3M

Key Statistics

Price/Earnings (Normalized)
37.50
Price/Sales
9.36
Dividend Yield (Trailing)
0.44%
Dividend Yield (Forward)
0.44%
Dividend Payment Schedule
Feb, May, Sep, Nov
Total Yield
0.81%

Company Profile

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
3,000
Website
https://www.bio-techne.com

Competitors

Valuation

View More
Metric
TECH
BIO
DHR
Price/Earnings (Normalized)
 37.5038.3226.08
Price/Book Value
 5.361.332.83
Price/Sales
 9.363.706.00
Price/Cash Flow
 34.1025.7921.01
Price/Earnings
TECH
BIO
DHR

Financial Strength

Metric
TECH
BIO
DHR
Quick Ratio
 2.942.141.03
Current Ratio
 4.553.141.65
Interest Coverage
 25.556.3816.95
Quick Ratio
TECH
BIO
DHR

Profitability

Metric
TECH
BIO
DHR
Return on Assets (Normalized)
 11.90%2.47%5.34%
Return on Equity (Normalized)
 15.03%3.53%8.59%
Return on Invested Capital (Normalized)
 12.96%2.66%6.45%
Return on Assets
TECH
BIO
DHR

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|FBRGC&LOCK|rk!R$128B
 Regeneron Pharmaceuticals Inc
REGN
LOCK|%lS!Q%^LOCK|$%&<&$76B
 Moderna Inc
MRNA
LOCK|&sB!NTLOCK|BM$75B
 argenx SE ADR
ARGX
LOCK|^?%SxzLOCK|!p$60B
 BeOne Medicines Ltd ADR
ONC
LOCK|VNC&dsJLOCK|mK?$44B
 Alnylam Pharmaceuticals Inc
ALNY
LOCK|gnJXpVmLOCK|s#dyG$31B
 Royalty Pharma PLC Class A
RPRX
LOCK|!!x%gCXFLOCK|&@$g$26B
 BioNTech SE ADR
BNTX
LOCK|<?Xc#hLOCK|$S%$24B
 Incyte Corp
INCY
LOCK|D<?ydbLOCK|jZD$24B
 Jazz Pharmaceuticals PLC
JAZZ
LOCK|w>$vY$LOCK|!Cl$15B

Sponsor Center